OpenAlex
PricingAboutJobs
Log inGet started
Work

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

HTML

Year: 2016
Type: article
Source: Clinical Pharmacokinetics
DOI: 10.1007/s40262-016-0405-4
Authors: Min Zhu, Benjamin Wu, Christian Brandl, Jessica Johnson, Andreas Wolf, Andrew Chow, Sameer Doshi
Institutions: Amgen (United States), Amgen (Germany)
Language: English

Topic: Acute Lymphoblastic Leukemia research
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: blinatumomab, bispecific T-cell engagers, CD19, pharmacokinetics, pharmacodynamics, relapsed/refractory B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, minimal residual disease, dosing regimen, cytokine production, creatinine clearance, drug interactions, T cell redistribution, B-cell depletion
SDG: Good health and well-being

Open Access status: closed

Funder: Amgen
OpenAlex ID: W2403074774
FWCI: 10.93
Cites: 38
Cited by: 231
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms